India Stays on U.S. IP Watch List, Pharma Patent Divide Persists

India has once again been placed on the United States’ “Priority Watch List” in the latest Special 301 Report, highlighting enduring differences between the two countries over pharmaceutical patent rules and access to affordable medicines.

The report, released on April 30 by the Office of the United States Trade Representative, raises concerns about India’s intellectual property (IP) framework, particularly provisions related to drug patents, data protection and enforcement. While the listing does not trigger immediate penalties, it is widely seen as a strategic tool used by Washington to shape future trade negotiations and policy engagement.

India’s inclusion is not new. The country has remained on the Priority Watch List since the 1990s, reflecting a long-standing policy divide over how intellectual property rights should be balanced with public health imperatives.

Pressure without legal bite

The Special 301 process is an administrative review rather than a binding legal mechanism. However, countries flagged in the report often face sustained diplomatic pressure and could encounter tougher demands during bilateral or multilateral trade negotiations.

This year, the report reviewed 25 countries. Vietnam was elevated to the “Priority Foreign Country” category—opening the door to a potential investigation—while India joins China, Chile, Indonesia, Russia and Venezuela in facing closer scrutiny.

Core dispute over pharma rules

At the center of the disagreement is India’s approach to pharmaceutical patents, which U.S. authorities argue is restrictive. Washington has consistently pushed for “TRIPS-plus” standards—rules that go beyond the baseline obligations under the WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights.

India, however, maintains that its framework is fully WTO-compliant and intentionally designed to safeguard access to affordable medicines.

One of the most contested provisions is Section 3(d) of India’s patent law, which prevents the patenting of new forms of known drugs unless they demonstrate enhanced therapeutic efficacy. The provision aims to curb “evergreening,” a practice where minor modifications are used to extend patent monopolies.

The clause was upheld in the landmark Novartis v. Union of India ruling, which denied a patent for a modified cancer drug and enabled the entry of far cheaper generics.

Similarly, U.S. concerns over India’s compulsory licensing provisions—allowing domestic firms to produce patented drugs under specific conditions—persist. India has exercised this power only once, in Bayer Corporation v. Natco Pharma Ltd., to expand access to a high-cost cancer treatment.

Data exclusivity and affordability

Another sticking point is India’s refusal to provide data exclusivity for pharmaceutical products. The U.S. typically seeks a minimum five-year protection period for clinical trial data, arguing it supports innovation.

India counters that such exclusivity is not mandated under TRIPS and would delay generic entry, significantly increasing drug costs. Health experts warn that adopting these provisions could restrict access to essential medicines, particularly in low- and middle-income countries.

Global stakes

India’s position carries global implications. The country supplies nearly 20% of the world’s generic medicines, with such drugs often reducing treatment costs by up to 90%. Its role as a major exporter of affordable medicines has made it central to healthcare systems across the developing world—and even in advanced economies.

Ajay Srivastava of the Global Trade Research Initiative said yielding to U.S. demands could have far-reaching consequences. “Accepting U.S. demands would weaken India’s generics industry—often called the ‘pharmacy of the world’—and harm patients globally, including in the U.S.,” he said.

He added that India should resist external pressure to dilute key safeguards. “India should avoid diluting critical provisions such as Section 3(d) and compulsory licensing, and must ensure its intellectual property regime is not compromised through commitments in future free trade agreements,” Srivastava said.

Enforcement and broader concerns

Beyond patents, the U.S. report flags issues such as enforcement gaps, including piracy, counterfeiting and judicial delays. It also points to the absence of a dedicated trade secrets law and the impact of drug price controls.

Indian authorities argue these are operational challenges rather than systemic weaknesses. Trade secrets, they note, are protected through contracts and common law, while price regulation—overseen by the National Pharmaceutical Pricing Authority—remains essential in a price-sensitive market.

They also highlight ongoing reforms aimed at improving patent processing timelines and strengthening enforcement capacity.

An enduring policy divide

The dispute ultimately reflects a deeper philosophical divide. The U.S. model emphasizes stronger IP protections to incentivize innovation, while India’s framework—anchored in the Patents Act, 1970—prioritizes public health and affordability.

With trade negotiations expected to intensify in the coming years, intellectual property—particularly in pharmaceuticals—is likely to remain a key flashpoint.

For now, India appears firm in its stance, signaling that its role as a global supplier of affordable medicines will not be easily compromised.

Related posts:

Ease of Doing Business Boost as Jan Vishwas Act Decriminalizes Cantonment Norms Strengthening the Partnership with India is Key to Tackling the Global Synthetic Drug Crisis India Confronts ‘Profit-First’ Drug Pricing as Multinational Pharma Firms Accused of Exploiting Regulatory Gaps India’s UK Trade Pact Faces Heat for Prioritizing Optics Over Sovereignty